According to Fimea's strategy, Fimea's research activities are based on the Act on the Finnish Medicines Agency and on the Pharmaceutical Policy 2020 statement of the Ministry of Social Affairs and Health. General operational goals include promoting the wellbeing of the population, improving public health, optimising health care costs with rational use of medicines, and contributing to social decision-making. Under law, Fimea's research areas are pharmacoepidemiology, pharmacoeconomy and pharmaceutical policy.
The structures and operating conditions of the pharmaceutical sector
The availability of medicines in all circumstances is the cornerstone of good pharmaceutical services. Important research areas include the significance of medicines in health care, the market entry of new medicines, the provision of pharmaceutical services, the effectiveness and coverage of pharmaceutical distribution services, and the provision of medicines information.
Rational pharmacotherapy consists of efficiency, safety, appropriateness, economy and feasibility. Population studies help to analyse: pharmacotherapies in practice, the sources of medicines information, access to and understanding of such information, the responsibilities of the user of medicines and their participation in the pharmacotherapy, and the role of medicines information in the promotion of rational pharmacotherapy. Research targeting the health care sector offers data on medicine prescription practices, the adoption of a multi-professional approach and the role of this approach in the patient's pharmacotherapy.
The effects and effectiveness of pharmacotherapy
In a rapidly changing operating environment, it is important to ensure product safety, but also to promote medication safety in the prescription, handling and consumption of medicines. Important research areas include the effectiveness of medicines, medicine and medication safety, and the costs and cost-effectiveness of pharmacotherapies.